Advertisement

Locally Advanced, Locally Recurrent, and Metastatic Breast Cancer

  • G. Fleming
Chapter
  • 112 Downloads

Abstract

Two tumor markers are approved by the Food and Drug Administration for the early detection of recurrent disease in breast cancer patients who have stage II and III disease: CA27.29 and CA15-3. The marketed assays use antibodies which recognize similar but not equivalent epitopes on a mucin-like membrane glycoprotein (the product of the MUC-1 gene), which is shed from tumor cells into the serum. These tests are not suitable for screening, as they are rarely positive in early-stage disease. CA27.29, which has been suggested to be more sensitive than CA15-3, is elevated in only 29% of woman with stage I disease, 36 % of women with stage II disease, and 59% of women with stage III disease. CA15-3 and CA27.29 may also be elevated in other malignancies, such as ovarian or pancreatic cancer, as well in as patients with benign conditions, particularly kidney and liver disease.

Keywords

Breast Cancer Clin Oncol Metastatic Breast Cancer Advanced Breast Cancer Radiat Oncol Biol Phys 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chan DW, Beveridge RA, Muss H, Fitsche HA et al (1997) Use of truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15:2322–2328PubMedGoogle Scholar
  2. 2.
    American Society of Clinical Oncology (2000) 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865–1878Google Scholar
  3. 3.
    Fourquet A, Campana F, Zafrani B et al (1989) Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 17:719–725PubMedCrossRefGoogle Scholar
  4. 4.
    Kurtz JM, Amalric R, Brandone H et al (1989) Local recurrence after breast-conserving surgery and radiotherapy: frequency, time course, and prognosis. Cancer 63:1912–1917PubMedCrossRefGoogle Scholar
  5. 5.
    Veronesi U, Marubini E, Del Vecchio M et al (1995) Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87:19–27PubMedCrossRefGoogle Scholar
  6. 6.
    Heimann R, Powers C, Halpern HJ et al (1996) Breast preservation in stage I and II carcinoma of the breast. Cancer 78:1722–1730PubMedCrossRefGoogle Scholar
  7. 7.
    Orel SG, Troupin RH, Patterson EA et al (1992) Breast cancer recurrence after lumpectomy and irradiation: role of mammography in detection. Radiology 183:201–206PubMedGoogle Scholar
  8. 8.
    Solin LJ, Fowble BL, Schultz DJ et al (1990) The detection of local recurrence after definitive irradiation for early stage carcinoma of the breast: an analysis of the results of breast biopsies performed in previously irradiated breasts. Cancer 65:2497–2502PubMedCrossRefGoogle Scholar
  9. 9.
    Boyages J, Bilous M, Barraclough B et al (1988) Fat necrosis of the breast following lumpectomy and radiation therapy for early breast cancer. Radiother Oncol 13:69–74PubMedCrossRefGoogle Scholar
  10. 10.
    Fowble B, Solin L, Schultz D et al (1991) Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys 19:833–842CrossRefGoogle Scholar
  11. 11.
    Recht A, Schnitt SJ, Connolly JL et al (1989) Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma. Int J Radiat Oncol Bio Phys 16:3–9CrossRefGoogle Scholar
  12. 12.
    Fisher B, Anderson S, Fisher ER et al (1991) Significance of ipsilateral breast tumor recurrence after lumpectomy. Lancet 338:327–331PubMedCrossRefGoogle Scholar
  13. 13.
    Haffty BG, Reiss M, Beinfield M et al (1996) Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol 14:52–57PubMedGoogle Scholar
  14. 14.
    Gage I, Schnitt SJ, Recht A et al (1998) Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol 16:480–486PubMedGoogle Scholar
  15. 15.
    Abner AL, Recht A, Eberlein T et al (1993) Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 11:44–48PubMedGoogle Scholar
  16. 16.
    Beck TM, Hart NE, Woodard DA et al (1983) Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. J Clin Oncol 1:400–405PubMedGoogle Scholar
  17. 17.
    Recht A, Gray R, Davidson NE et al (1999) Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17:1689–1700PubMedGoogle Scholar
  18. 18.
    Overgaard M, Hansen PS, Overgaard J et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949–962PubMedCrossRefGoogle Scholar
  19. 19.
    Nolvadex Adjuvant Trial Organisation (1988) Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57:608–611CrossRefGoogle Scholar
  20. 20.
    Aberizk WJ, Silver B, Henderson C et al (1986) The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 58:1214–1218PubMedCrossRefGoogle Scholar
  21. 21.
    Kamby C, Sengelov L (1997) Patterns of dissemination and survival following isolated locoregional recurrence of breast cancer. BrJ Cancer Res Treat 45:181–192CrossRefGoogle Scholar
  22. 22.
    Fentiman IS, Matthews PN, Davison OW et al (1985) Survival following local skin recurrence after mastectomy. Br J Surg 72:14–16PubMedCrossRefGoogle Scholar
  23. 23.
    Baral E, Ogenstad S, Wallgren A (1985) The effect of adjuvant radiotherapy on the time of occurrence and prognosis of local recurrence in primary operable breast cancer. Cancer 56:2779–2782PubMedCrossRefGoogle Scholar
  24. 24.
    Tennvall-Nittby L, Tengrup I, Landberg T (1993) The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. Acta Oncol 32:614–646CrossRefGoogle Scholar
  25. 25.
    Fentiman IS, Lavelle MA, Caplan D et al (1986) The significance of supraclavicular fossa node recurrence after radical mastectomy. Cancer 57:908–910PubMedCrossRefGoogle Scholar
  26. 26.
    Recht A, Pierce SM, Abner A et al (1991) Regional nodal failure after conservative surgery and radiotherapy for earlystage breast carcinoma. J Clin Oncol 9:988–996PubMedGoogle Scholar
  27. 27.
    Fowble B, Solin L, Schultz D et al (1989) Frequency, sites of relapse, and outcome of regional node failures following conservation surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys 17:703–710PubMedCrossRefGoogle Scholar
  28. 28.
    Seidman H, Gelb SK, Silverberg E et al (1987) Survival experience in the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 37:258–290PubMedCrossRefGoogle Scholar
  29. 29.
    Mourali N, Muenz LR, Tabbane F et al (1980) Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 46:2741–2746PubMedCrossRefGoogle Scholar
  30. 30.
    Haagensen CD (1943) Carcinoma of the breast: criteria of inoperability. Ann Surg 118:859–870PubMedGoogle Scholar
  31. 31.
    Brito RA, Valero V, Buzdar AU et al (2001) Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19:628–633PubMedGoogle Scholar
  32. 32.
    American Joint Committee on Cancer (1998) Breast. In: Fleming ID, Cooper JS, Henson DE et al (eds) AJCC Cancer Staging Handbook. Lippincott-Raven, Philadelphia, p 149Google Scholar
  33. 33.
    Lucas FV, Perez-Mesa C (1978) Inflammatory carcinoma of the breast. Cancer 41:1595–1605PubMedCrossRefGoogle Scholar
  34. 34.
    Levine P, Steinhorn S, Ries LG et al (1985) Inflammatory breast cancer. The experience of the Surveillance Epidemiology and End Result (SEER) Program. J Natl Cancer Inst 74:291–297PubMedGoogle Scholar
  35. 35.
    Jaiyesimi IA, Buzdar AU, Hortobagyi G (1992) Inflammatory breast cancer: a review. J Clin Oncol 10:1014–1024PubMedGoogle Scholar
  36. 36.
    Abraham DC, Jones RC, Jones SE et al (1996) Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78:91–100PubMedCrossRefGoogle Scholar
  37. 37.
    Parker SL, Tong T, Bolden S (1997) Cancer statistics, 1997. CA Cancer J Clin 47:5–27PubMedCrossRefGoogle Scholar
  38. 38.
    Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746PubMedGoogle Scholar
  39. 39.
    Lamovec J, Bracko M (1991) Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 48:28–33PubMedCrossRefGoogle Scholar
  40. 40.
    Greenberg PAC, Hortobagyi GN, Smith TL et al (1996) Longterm follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205PubMedGoogle Scholar
  41. 41.
    Vogel CL, Azevedo S, Hilsenbeck S et al (1992) Survival after first recurrence of breast cancer. Cancer 70:129–135PubMedCrossRefGoogle Scholar
  42. 42.
    Rubens RD, Bajetta E, Bonneterre J et al (1994) Treatment of relapse of breast cancer after adjuvant systemic therapy — review and guidelines for future research. Eur J Cancer 30A:106–111PubMedCrossRefGoogle Scholar
  43. 43.
    Wittliff JL (1984) Steroid-hormone receptors in breast cancer. Cancer 53:630–643PubMedCrossRefGoogle Scholar
  44. 44.
    Elledge RM, Green S, Ciocca D et al (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4:7–12PubMedGoogle Scholar
  45. 45.
    Mouridsen H, Gershenaovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 19:2596–2606PubMedGoogle Scholar
  46. 46.
    Klijn JGM, Beex LVAM, Mauriac L et al (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92:903–911PubMedCrossRefGoogle Scholar
  47. 47.
    Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453–461PubMedGoogle Scholar
  48. 48.
    Valagussa P, Brambilla C, Zambetti M et al (1989) Salvage treatments in relapsing resectable breast cancer. In: Senn HJ, Goldhirsch R, Gelber RD, Osterwalder B (eds) Recent results in cancer research (vol 115). Springer, Berlin Heidelberg New York, pp 69–76Google Scholar
  49. 49.
    Swain SM, Whaley FS, Gerber MC et al (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333–1340PubMedGoogle Scholar
  50. 50.
    Gregory WM, Smith P, Richard MA et al (1993) Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 68:988–995PubMedCrossRefGoogle Scholar
  51. 51.
    Muss HB, Case LD, Richards F et al (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325:1342–1348PubMedCrossRefGoogle Scholar
  52. 52.
    Coates A, Gebski V, Bishop JF et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 317:1490–1495PubMedCrossRefGoogle Scholar
  53. 53.
    Tannock IF, Boyd NF, DeBoer G et al (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 5:1377–1387Google Scholar
  54. 54.
    Brufman G, Colajori E, Ghilezan N et al (1997) Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Ann Oncol 8:155–162PubMedCrossRefGoogle Scholar
  55. 55.
    Stadtmauer EA, O’Neill A, Goldstein LJ et al (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342:1069–1072PubMedCrossRefGoogle Scholar
  56. 56.
    Baselga J, Tripathy D, Mendelsohn J et al (1996) Phase II study of weekly intravenous recombinant humanized anti-pl85HER2 monoclonal antibody in patients with HER2/ nfor metastatic breast cancer. J Clin Oncol 14:737–744PubMedGoogle Scholar
  57. 57.
    Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648PubMedGoogle Scholar
  58. 58.
    Vogel C, Cobleigh M, Tripathy D et al (2000) First-line non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 monoclonal antibody) (abstract no. 275). Proc Am Soc Clin Oncol 19:71AGoogle Scholar
  59. 59.
    Slamon DJ, Leyland-Jones B, Shak S (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  60. 60.
    Burstein HJ, Kuter I, Campos SM et al (2001) Clinical activity of trastuzumab and vinorelbine in women with her2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722–2730PubMedGoogle Scholar
  61. 61.
    Vogel CL, Schoenfelder J, Shemano I et al (1995) Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 13: 1123–1128PubMedGoogle Scholar
  62. 62.
    Janicek M, Hayes DF, Kaplan WD (1994) Healing flare in skeletal metastases from breast cancer. Radiology 192: 201–204PubMedGoogle Scholar
  63. 63.
    Bloomfield DJ (1998) Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16:1218–1225PubMedGoogle Scholar
  64. 64.
    Conte PF, Latreille J, Calabresei MF et al (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14:2552–2559PubMedGoogle Scholar
  65. 65.
    Hortobagyi GN, Theriault RL, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785–1837PubMedCrossRefGoogle Scholar
  66. 66.
    Borner M, Bacchi M, Goldhirsch A et al (1994) First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol 12:2071–2077PubMedGoogle Scholar
  67. 67.
    Schaake-Koning C, Hamersma Von der Linden E, Hart G et al (1985) Adjuvant chemo-and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys 11:1759–1763PubMedCrossRefGoogle Scholar
  68. 68.
    Pierce LJ, Lippman M, Ben-Baruch N et al (1992) The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Rad Oncol Biol Phys 23:949–960CrossRefGoogle Scholar
  69. 69.
    Ueno NT, Buzdar AU, Singletary SE et al (1997) Combinedmodality treatment of inflammatory breast carcinoma: twenty years of experience at M.D.Anderson Cancer Center. Cancer Chemother Pharmacol 40:321–329PubMedCrossRefGoogle Scholar
  70. 70.
    Graham MV, Perez CA, Kuske RK et al (1991) Locally advanced (Noninflammatory) carcinoma of the breast: results and comparison of various treatment modalities. Int J Rad Oncol Biol Phys 21:311–318CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • G. Fleming

There are no affiliations available

Personalised recommendations